Didier has 30 years’ experience in drug delivery using colloids, ranging from basic research to clinical trials. He has collaborated with BioChem Pharma, GSK, Sanofi Pasteur and Chiron-Novartis on the evaluation of nasal vaccine using nanotechnologies. As an international expert in nanomedicine, he presided at the French Society for Controlled Release, was a board member of the French Society of Nanomedicine, and has over 110 international publications and 23 patents.
After a PhD on drug targeting in collaboration with the World Health Organization, Didier developed a patented technology for vaccine applications based on polysaccharidic nanoparticles with a phospholipid bi-layer.
His experience, innovative research and patented technology are at the heart of Vaxinano.
Boris has a strong experience as business and licensing director, specialized in pharmaceutic and in medical devices. He supported the technology transfer of academic research by the creation of 13 start-ups and the signing of more than 35 license agreements.
Holding a PhD in physics with the CEA of Grenoble, France, consolidated by a post-doctoral position in the University of Twente in the Netherlands, he was project manager and scientist in UK and Belgium (Imperial chemical industries, Flamac, Umicore, Agfa). He then engaged this international R&D experience into Biotech Company and start-up development, managing the IP, the licensing and patent strategy, the technology transfer and the business model for 10 years.
He joined Vaxinano as Administrative Director.
Rémi is the Chief Financial Officer of Vaxinano since January 2021. He has a strong experience in corporate finance and fundraising.
Previously, Rémi started his career with KPMG in Transaction Services and Accounting Advisory. He also supported startups in modeling business plan and seeking financing. In 2014, Rémi joined a Med-Tech start-up as CFO and achieved with success 3 fundraisings. He demonstrated his skills and capability in strategy definition and implementation, finance & controlling.
Rémi holds two Masters in Finance, Accounting and Auditing from the University School of Management of Lille.
Angelo joined VAXINANO in May 2019 as a project manager, with 7 years of experience as an engineer and then R&D manager in a start-up specialized in microbiology and fermentative metabolites. He successfully managed the different key R&D steps starting with the characterization of fermentative metabolites, the design and follow-up of pre-clinical studies, the standardization of production and the transfer to a pharmaceutical structure for marketing .
Within Vaxinano, he is now in charge of monitoring and coordinating vaccine development projects.
He holds a PhD in microbiology, immunology, virology and parasitology from the University of Lille and a Master's degree in Biotechnology with a specialization in genomics and proteomics from the University of Lille.